Literature DB >> 12900034

Characterization of In111, a class 1 integron that carries the extended-spectrum beta-lactamase gene blaIBC-1.

S Vourli1, L S Tzouvelekis, E Tzelepi, E Lebessi, N J Legakis, V Miriagou.   

Abstract

A class 1 integron, In111, carried by a self-transferable plasmid from an Escherichia coli clinical strain was characterized. The variable region of In111 constituted an array of gene cassettes encoding the extended-spectrum beta-lactamase IBC-1, the aminoglycoside-modifying enzymes AAC(6')-Ib and ANT(3")-Ia, dihydrofolate reductase I and a putative polypeptide (SMR-2) sharing similarity with the Qac transporters. Transcription of the gene cassettes was driven by a hybrid-type P1 promoter located in a typical 5' conserved segment (CS). The 3'CS included sulI, qacEDelta1, orf5 and orf6. In111 was bounded on the right by an inversely oriented IRt. The 5'CS was preceded by an intact IS26 element followed by an aphA1 gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900034     DOI: 10.1016/S0378-1097(03)00510-X

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  10 in total

1.  CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid.

Authors:  V Miriagou; L S Tzouvelekis; L Villa; E Lebessi; A C Vatopoulos; A Carattoli; E Tzelepi
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Mosaic structure of p1658/97, a 125-kilobase plasmid harboring an active amplicon with the extended-spectrum beta-lactamase gene blaSHV-5.

Authors:  M Zienkiewicz; I Kern-Zdanowicz; M Gołebiewski; J Zyliñska; P Mieczkowski; M Gniadkowski; J Bardowski; P Cegłowski
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  IS26-associated In4-type integrons forming multiresistance loci in enterobacterial plasmids.

Authors:  Vivi Miriagou; Alessandra Carattoli; Eva Tzelepi; Laura Villa; Leonidas S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa.

Authors:  Ines Schneider; Anne Marie Queenan; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Diversity of clavulanic acid-inhibited extended-spectrum β-lactamases in Aeromonas spp. from the Seine River, Paris, France.

Authors:  Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

Review 6.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A beta-lactamase, GES-4, possessing a single G170S substitution in the omega-loop.

Authors:  Jun-ichi Wachino; Yohei Doi; Kunikazu Yamane; Naohiro Shibata; Tetsuya Yagi; Takako Kubota; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan.

Authors:  Jun-ichi Wachino; Yohei Doi; Kunikazu Yamane; Naohiro Shibata; Tetsuya Yagi; Takako Kubota; Hideo Ito; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Sequence types 235, 111, and 132 predominate among multidrug-resistant pseudomonas aeruginosa clinical isolates in Croatia.

Authors:  Marija Guzvinec; Radosław Izdebski; Iva Butic; Marko Jelic; Maja Abram; Iva Koscak; Anna Baraniak; Waleria Hryniewicz; Marek Gniadkowski; Arjana Tambic Andrasevic
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

10.  Diversity and evolution of the small multidrug resistance protein family.

Authors:  Denice C Bay; Raymond J Turner
Journal:  BMC Evol Biol       Date:  2009-06-23       Impact factor: 3.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.